Scientists test if more doses of cancer vaccine can sharpen Body's defenses

NCT ID NCT05806814

Summary

This small, early-stage study is testing whether giving more doses of an existing prostate cancer immunotherapy, called Sipuleucel-T, can create a stronger immune response against the cancer. It will involve about 13 men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The main goal is to see if this extended treatment schedule is practical and if it changes how the patient's immune system reacts.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Oklahoma Health Sciences Center, Stephenson Cancer Center

    RECRUITING

    Oklahoma City, Oklahoma, 73114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.